We are committed to the highest standards of corporate governance to ensure the long-term success of the company and to promote the interests of our shareholders.
Former FDA Commissioner. Expert in regulatory strategy.
Marcus Thorne
Lead Independent Director
30 years in Investment Banking (BioTech M&A).
Sarah Jin
CEO & Director
Founder. PhD in Computational Biology from MIT.
Robert Chen
Director
Managing Partner at Sequoia Capital.
Elena Rodriguez
Independent Director
Professor of Structural Engineering, ETH Zurich.
Founder Transition
Per the 2024 Shareholder Agreement, Founder voting rights (Class B) will sunset automatically upon the earlier of (i) 2030 or (ii) the reduction of ownership below 10%.